CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics

Cited by papers we hold 3

• Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective · 2020
  No notice
• Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects · 2020
  No notice
• The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.